Biologics Inc., an oncology pharmacy services company under the McKesson Specialty Health umbrella, recently announced that Pfizer selected it to distribute Besponsa, a new IV therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Besponsa was approved by the U.S. Food and Drug Administration as an antibody-drug conjugated to calicheamicin. It targets the marker CD22 which, according to Biologics, is expressed in more than 90 percent of patients with B-cell ALL.
“Clinical trial results for BESPONSA are very impressive, demonstrating significant clinical benefits,” Brandon Tom, vice president of Biopharma Services at McKesson Specialty Health, said in a statement. “We look forward to being a specialty pharmacy provider for this exciting new therapy that could potentially play a role in changing the treatment landscape for ALL.”
Biologics is part of McKesson Specialty Health, which is a division of McKesson Corp. The specialty health group works to empower the community patient care delivery system through community-based advancement of science, technology and quality of care.